AI Diagnostics Land in the UK

Align Technology launched its AI-powered radiograph analysis tool, Align X-ray Insights, in the EU and UK in March 2025. This isn’t a startup demo or a proof of concept. It’s a major industry player, the company behind Invisalign and iTero, rolling out AI diagnostics across European practices. For British dentistry, I think it marks a real turning point.

What it actually does

Align X-ray Insights is a cloud-based detection tool that uses AI to analyse 2D radiographs automatically. It identifies caries, periapical radiolucencies, and periodontal bone loss: the bread and butter of diagnostic radiology in general practice.

The software became available in the EU and UK from 25 March 2025 and was showcased at IDS in Cologne. It integrates with Align’s existing digital platform, including the iTero scanner ecosystem, and can be accessed from any desktop or tablet.

Align acquired the underlying technology through its purchase of dentalXrai GmbH in 2022. The product has regulatory clearance in Europe, the UK, Canada, and New Zealand, with US 510(k) clearance still pending.

The early numbers look promising

According to Align’s data from early users, 95% of dentists found the software helpful for communicating oral health conditions to patients. 91% reported it increased treatment acceptance for restorative procedures and contributed to higher patient trust during discussions.

These are manufacturer-reported figures from early adopters, so they need appropriate caution. But the direction is clear: AI diagnostics aren’t just about finding pathology. They’re about helping patients understand what’s going on in their mouths. The AI-annotated radiograph becomes a communication tool as much as a diagnostic one.

Why this matters for UK dentists

We’ve been watching AI diagnostics develop largely from the sidelines. Most of the action (FDA clearances, large-scale DSO rollouts, clinical studies) has been happening in the US. Companies like Pearl, Overjet, and VideaAI built their market presence primarily across the Atlantic.

Align’s launch changes the dynamic. For the first time, a company that virtually every UK dentist already knows and works with is offering AI diagnostics that are regulatory-cleared and commercially available here. That’s meaningful.

It also normalises AI diagnostics in the European context. When the tool comes from the same company that supplies your aligner system and your intraoral scanner, it stops being an exotic add-on from a Silicon Valley startup. It’s part of your existing digital workflow.

Ready but cautious

My sense from colleagues is that British dentists are interested but cautious, and both reactions are genuine.

Most of us can see the value of a second pair of AI eyes on our radiographs, particularly for subtle early caries or borderline periodontal findings. The caution comes from several places:

• Evidence. UK dentists tend to want robust, independent clinical evidence before changing workflows. Manufacturer data is a starting point, not an endpoint. We need peer-reviewed studies in UK and European populations with follow-up on clinical outcomes.
• Regulation. The MHRA has launched a national commission to examine AI regulation in healthcare, and until that framework settles, some practitioners will understandably hold back.
• Integration. UK practices run on a variety of software systems. Cloud-based delivery helps, but there are still questions about speed, reliability, and how AI fits into clinical decision-making.

Private sector will lead, NHS will follow

If I had to predict the adoption pattern: private practices will lead. They have more flexibility in technology investments, more incentive to offer advanced diagnostics as a differentiator, and fewer bureaucratic hurdles.

NHS practices will likely follow years later, once there’s a critical mass of evidence, a clear regulatory framework, and realistically some kind of funding pathway that supports AI tool adoption. That’s not a criticism of the NHS; it’s just how large public health systems adopt new technology.

The bigger picture

The global AI dental imaging market is projected to reach over $3 billion by 2034, with Europe representing roughly 27% of global revenue. The radiograph analysis segment alone accounts for over 40% of the market. This is becoming mainstream.

Align’s move into the UK and EU is significant precisely because of who’s making it. When a company with Align’s scale, reputation, and existing relationships decides to invest in AI diagnostics, it signals something to the rest of the industry.

For UK dentists, my advice is straightforward: pay attention, stay curious, but don’t rush. Evaluate the evidence as it emerges, talk to colleagues using the tool, consider how it fits your workflow and patient communication, and keep one eye on the regulatory landscape. How the UK decides to regulate these tools will shape what’s available for years to come.

References

• Align Technology. “Align Technology Launches Align X-ray Insights, an AI Computer-Aided Detection Software, in the European Union and United Kingdom.” BusinessWire, 10 March 2025. businesswire.com
• Dentistry Today. “Align X-ray Insights Launches in Europe.” March 2025. dentistrytoday.com
• Knowledge Sourcing Intelligence. “AI In Dental Imaging Market Report 2030.” knowledge-sourcing.com
• Towards Healthcare. “AI in Dental Market to Grow at 21.78% CAGR till 2034.” towardshealthcare.com